Invention Grant
- Patent Title: VEGFR2/Ang2 compounds
- Patent Title (中): VEGFR2 / Ang2化合物
-
Application No.: US14709511Application Date: 2015-05-12
-
Publication No.: US09580499B2Publication Date: 2017-02-28
- Inventor: Donmienne Doen Mun Leung , Ling Liu , Jirong Lu , Ying Tang , Jianghuai Xu
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Robert Brian Johnson
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/00 ; C07K16/22 ; C07K16/40 ; C07K16/28
Abstract:
The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.
Public/Granted literature
- US20150329626A1 VEGFR2/Ang2 Compounds Public/Granted day:2015-11-19
Information query
